IP Library Granted Patent US 8,664,177
Granted Patent B2
US 8,664,177 · App. 13/371,042 · Granted Mar 4, 2014

Peptide compositions and methods for treating patients

Inventors: Yuqing E. Chen (Ann Arbor, MI); Changyong Xue (Ann Arbor, MI); Jifeng Zhang (Ann Arbor, MI)
Assignee: The Regents of the University of Michigan
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,664,177
App. No.
13/371,042
Granted
Mar 4, 2014
Kind
B2
Abstract

The present invention is directed to peptide compositions and methods of using the peptide compositions to treat prediabetes, diabetes, obesity, high blood pressure and metabolic syndrome.

Claims (9)

1. An oral pharmaceutical dosage form consisting essentially of at least one peptide consisting of the amino acid sequence GGL, GLL, GGdL, GdLL, GLdL or GdLdL, or a pharmaceutically acceptable salt of the peptide, and a pharmaceutically acceptable excipient.

2. The oral pharmaceutical dosage form of claim 1 , wherein the oral pharmaceutical dosage form consists essentially of at least one peptide consisting of the amino acid sequence GGL or GLL.

3. An oral pharmaceutical dosage form consisting essentially of at least one peptide consisting of the amino acid sequence GGL, GLL, GGdL, GdLL, GLdL or GdLdL, or a pharmaceutically acceptable salt of the peptide, and a pharmaceutically acceptable excipient wherein the peptide is acetylated at the N-terminus, amidated at the C-terminus, or both.

4. An oral pharmaceutical dosage form consisting essentially of at least one peptide consisting of the amino acid sequence GGL, GLL, GGdL, GdLL, GLdL or GdLdL, and one or more pharmaceutically acceptable excipients.

5. An oral pharmaceutical dosage form consisting essentially of at least one peptide consisting of the amino acid sequence GGL, GLL, GGdL, GdLL, GLdL or GdLdL, and one or more pharmaceutically acceptable excipients, wherein the peptide is acetylated at the N-terminus, amidated at the C-terminus, or both.

6. An oral pharmaceutical dosage form consisting essentially of a peptide consisting of the amino acid sequence GGL, and one or more pharmaceutically acceptable excipients.

7. An oral pharmaceutical dosage form consisting essentially of a peptide consisting of the amino acid sequence GGdL, and one or more pharmaceutically acceptable excipients.

8. The oral pharmaceutical dosage form of claim 1 , 2 , 3 , 4 , 5 , 6 or 7 , wherein the oral pharmaceutical dosage form is a solid dosage form.

9. The oral pharmaceutical dosage form of claim 1 , 2 , 3 , 4 or 5 wherein the at least one peptide is two or more of the peptides consisting of the amino acid sequence GGL, GLL, GGdL, GdLL, GLdL or GdLdL.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 22, 2012
From: CHEN, YUQING E.; ZHANG, JIFENG; XUE, CHANGYONG
To: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Reel/Frame 028248/0561 →
CONFIRMATORY LICENSE Recorded Mar 2, 2012
From: UNIVERSITY OF MICHIGAN
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 027794/0155 →
Continuity (2)
Provisional Application 61441748 · Feb 11, 2011
Related Publication 20120208748A1 · Aug 16, 2012